Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model.
about
Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemia'Trained immunity': consequences for lymphoid malignanciesUsing Murine Models to Investigate Tumor-Lymphoid Interactions: Spotlight on Chronic Lymphocytic Leukemia and Angioimmunoblastic T-Cell Lymphoma.Microenvironment abnormalities and lymphomagenesis: Immunological aspects.Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies.Spontaneous onset and transplant models of the Vk*MYC mouse show immunological sequelae comparable to human multiple myeloma.Phenotypic alteration of CD8+ T cells in chronic lymphocytic leukemia is associated with epigenetic reprogramming.New Pharmacotherapies in Chronic Lymphocytic Leukemia.The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.The emerging role of immune checkpoint inhibition in malignant lymphoma.Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia.The PD-1/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia.Interferon-related secretome from direct interaction between immune cells and tumor cells is required for upregulation of PD-L1 in tumor cells.Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk.Higher PD-1 expression concurrent with exhausted CD8+ T cells in patients with de novo acute myeloid leukemia.IFNγ induces PD-L1 overexpression by JAK2/STAT1/IRF-1 signaling in EBV-positive gastric carcinoma.Restrictions in the T-cell repertoire of chronic lymphocytic leukemia: high-throughput immunoprofiling supports selection by shared antigenic elements.Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia.CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells.TNF receptor signaling is a driver of chronic lymphocytic leukemia that can be therapeutically targeted by the flavonoid wogonin.Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.Overcoming Barriers of Age to Enhance Efficacy of Cancer Immunotherapy: The Clout of the Extracellular Matrix.NF-κB p50 (nfkb1) contributes to pathogenesis in the Eμ-TCL1 mouse model of chronic lymphocytic leukemia.Targeting the Adenosinergic Axis in Chronic Lymphocytic Leukemia: A Way to Disrupt the Tumor Niche?Aberrant Immunological Synapses Driven by Leukemic Antigen-Presenting Cells.Potent anti-leukemic activity of a specific cyclin-dependent kinase 9 inhibitor in mouse models of chronic lymphocytic leukemia.
P2860
Q26768154-906A6025-0B8C-4F4C-BF31-E21E70A21A4FQ26773053-C7EA6BC3-812C-4000-BA32-2983FE601AAEQ28074639-8369A385-02BB-4A1F-B691-DCEE9F3DE843Q33621881-86749BD4-85EF-4C66-AD58-D2417EC56C02Q36118020-3AA03E8B-705C-47B5-889D-5F0B48D9EE07Q36522770-73F3D4A3-21EE-4ED4-807E-134CCE770F6CQ37233276-3443D092-710D-4204-98BD-7C0A3792FA8DQ37457945-A07B550A-9879-41C7-9F98-88F9A8DBFB69Q37605306-848731A4-8FE7-488A-B8F5-8FD48B8BCD8DQ38775177-35D5F0F5-2222-4952-BC5A-0CC8CAE6622BQ38791036-11ED57CF-150C-4DEB-B636-B15C5469CD80Q39092611-5CABF3CC-BBCE-429C-8C91-66EC016E7E63Q39538318-102F04F3-F7E8-44B8-8779-BE84E83BEA7DQ42436960-181F0AD0-E8B2-428E-B917-6EB8B9D8958DQ46011813-F406B9C4-D72B-414F-9564-7C036C357CFDQ47151143-13FAEC2A-3034-4446-881E-D3D4D66E4333Q47273046-A68AF1F6-4F2D-4046-94C5-E7995AEB0006Q48187234-5937BE88-CC2A-42C1-8EE0-1D08C3637137Q50028314-8D0499C5-B8AC-4C08-923E-93DBF8409A12Q50030507-D0B5BD9E-01B8-43BA-89AE-BD53139CE2F8Q50078371-E82232C6-D039-4157-8E78-B47BC3AC0681Q50716088-D42E9B25-6DD9-42D3-A7EF-E0D396A92F46Q51762655-E664D5AE-1C53-4D8B-8688-A3C25119388BQ51822007-063302A6-60B6-4F7F-A699-152AB246A6DDQ52323624-1A0D1F22-C55D-4102-832E-A01B1FC2BD5BQ52897863-B7F5E00F-7E05-44D7-BD77-FF4ABFF4292EQ55280895-DF15A05D-5D97-4F21-BCC7-DC4853760DC6
P2860
Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Mechanisms of PD-L1/PD-1-media ...... n the Eµ-TCL1 CLL mouse model.
@ast
Mechanisms of PD-L1/PD-1-media ...... n the Eµ-TCL1 CLL mouse model.
@en
type
label
Mechanisms of PD-L1/PD-1-media ...... n the Eµ-TCL1 CLL mouse model.
@ast
Mechanisms of PD-L1/PD-1-media ...... n the Eµ-TCL1 CLL mouse model.
@en
prefLabel
Mechanisms of PD-L1/PD-1-media ...... n the Eµ-TCL1 CLL mouse model.
@ast
Mechanisms of PD-L1/PD-1-media ...... n the Eµ-TCL1 CLL mouse model.
@en
P2093
P2860
P50
P1433
P1476
Mechanisms of PD-L1/PD-1-media ...... in the Eµ-TCL1 CLL mouse model
@en
P2093
Eleni Kotsiou
John C Riches
Shaun Miller
William P Day
P2860
P304
P356
10.1182/BLOOD-2015-02-626754
P407
P577
2015-05-15T00:00:00Z